AR045006A1 - Derivados de quinazolinona 5-sustituidos - Google Patents
Derivados de quinazolinona 5-sustituidosInfo
- Publication number
- AR045006A1 AR045006A1 ARP040102347A ARP040102347A AR045006A1 AR 045006 A1 AR045006 A1 AR 045006A1 AR P040102347 A ARP040102347 A AR P040102347A AR P040102347 A ARP040102347 A AR P040102347A AR 045006 A1 AR045006 A1 AR 045006A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- ring
- aryl
- independently selected
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 3
- -1 cyano, hydroxyl Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 206010020880 Hypertrophy Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000026723 Urinary tract disease Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Los compuestos son antagonistas del adrenoreceptor alfa-1 A/B y se utilizan para el tratamiento de trastornos y síntomas del tracto urinario, disfunción sexual, hipertrofia benigna de próstata y dolor. Reivindicación 1: Un compuesto de la fórmula (1), en donde: Z es -C(=O)- ó -S(=O)2-; R y R' son alquilo inferior; R5 se selecciona de halógeno, ciano, hidroxilo, fenilo opcionalmente sustituido, -R6, y -OR6; R6 es alquilo, alcoxialquilo, hidroxialquilo, benciloxi-alcoxilo opcionalmente sustituido, fenoxilo opcionalmente sustituido, aminoalquilo, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo, o cicloalquiloxilo; y Q es un anillo heterocíclico bicíclico o monocíclico seleccionado de un resto de grupo de fórmula (2), en donde: B es un anillo heteroarilo o arilo fusionado opcionalmente sustituido; R7 está unido a cualquier átomo de carbono disponible del anillo de piperidinilo o piperazinilo y en cada caso se selecciona independientemente de alquilo, alquilo sustituido, halógeno, ciano, hidroxilo, alcoxilo, haloalcoxilo, amino y alquilamino; o alternativamente, en donde Q es anillo (T), dos grupos R7 unidos a diferentes átomos de carbono se pueden tomar juntos para formar un puente carbono-carbono de uno o dos átomos de carbono como cabeza de puente; R8 es -K-R14; R9 y R10 se i) seleccionan independientemente de -L-R15, o alternativamente, ii) R9 y R10 se toman juntos para formar un anillo espirocíclico opcionalmente sustituido; K y L se seleccionan independientemente de un enlace, C1-4 alquileno opcionalmente sustituido, -M1-O-M2-, -M1-C(=O)-M2-, -M1C(O)2-M2-, -M1-C(=O)NR16-M2-, y -M1-NR16-M2-, en donde M1 y M2 se seleccionan de un enlace y C1-4 alquileno opcionalmente sustituido; R14 y R15 se seleccionan independientemente de hidrógeno, alquilo opcionalmente sustituido, arilo, heteroarilo, cicloalquilo, o heterociclo, proporcionando que si K ó L es un enlace o -NR16-, entonces R14 y R15 no se seleccionan de fenilo, piridilo, o pirimidinilo con un sustituyente en para que es CO2R22, en donde R22 se selecciona de hidrógeno, alquilo, arilo, arailalquilo, guanidinilo, hidroxilo, alcoxilo, ariloxilo, y arilalquiloxilo; R16 se selecciona de hidrógeno y alquilo; m es 0, 1, 2, 3 ó 4; n es 0 ó 1; p es 0, 1 ó 2; y q es 0 ó 1; o un isómero o sal farmacéuticamente aceptable, hidrato o profármaco del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48453603P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045006A1 true AR045006A1 (es) | 2005-10-12 |
Family
ID=34062053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102347A AR045006A1 (es) | 2003-07-02 | 2004-07-02 | Derivados de quinazolinona 5-sustituidos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050124607A1 (es) |
| EP (1) | EP1644343B1 (es) |
| JP (1) | JP2009513504A (es) |
| KR (1) | KR100737036B1 (es) |
| CN (1) | CN1845908A (es) |
| AR (1) | AR045006A1 (es) |
| AT (1) | ATE366242T1 (es) |
| AU (1) | AU2004255585A1 (es) |
| BR (1) | BRPI0412163A (es) |
| CA (1) | CA2530450A1 (es) |
| DE (1) | DE602004007387T2 (es) |
| ES (1) | ES2290726T3 (es) |
| MX (1) | MXPA06000185A (es) |
| PL (1) | PL1644343T3 (es) |
| RU (1) | RU2006102867A (es) |
| TW (1) | TW200514782A (es) |
| WO (1) | WO2005005397A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539180A4 (en) * | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| CN1884262B (zh) * | 2005-06-24 | 2014-06-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 4-氨基哌啶类化合物及其医药用途 |
| US8349850B2 (en) | 2006-03-28 | 2013-01-08 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN101225083A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| US8859538B2 (en) * | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| JP5485148B2 (ja) | 2007-06-21 | 2014-05-07 | カラ セラピューティクス インコーポレイテッド | 置換イミダゾ複素環 |
| CA2832822A1 (en) | 2011-04-10 | 2012-10-18 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| EP2864322B1 (en) | 2012-06-20 | 2016-04-27 | Novartis AG | Complement pathway modulators and uses thereof |
| CN107690429B (zh) * | 2015-04-07 | 2022-02-25 | Ela制药有限公司 | 用于治疗和/或预防细胞或组织坏死的组合物，其特异性靶向组织蛋白酶c和/或cela1和/或cela3a和/或与其结构相关的酶 |
| US10196383B2 (en) * | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| JP6964343B2 (ja) | 2015-11-20 | 2021-11-10 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン |
| WO2017164707A1 (ko) * | 2016-03-24 | 2017-09-28 | 주식회사 케미메디 | 전립선 비대증에서 기인한 방광출구폐색에 의해 2차적인 방광 변성으로 유발된 과민성 방광의 예방 또는 치료용 의약 조성물 및 건강기능식품 |
| ES2998084T3 (en) | 2017-12-27 | 2025-02-19 | Japanese Found For Cancer Res | Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor |
| CN113754594B (zh) * | 2021-09-16 | 2025-01-21 | 中国药科大学 | 喹唑啉酮类化合物或其可药用的盐、异构体及其制备方法、药物组合物和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084457A (en) * | 1990-07-23 | 1992-01-28 | American Cyanamid Company | Benzoylaminoquinazolinones |
| US5756502A (en) * | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| GB9700504D0 (en) * | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| US6156758A (en) * | 1999-09-08 | 2000-12-05 | Isis Pharmaceuticals, Inc. | Antibacterial quinazoline compounds |
| US6900220B2 (en) * | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
| ES2241891T3 (es) * | 2001-01-02 | 2005-11-01 | F. Hoffmann-La Roche Ag | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b. |
| GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
-
2004
- 2004-06-29 JP JP2006518051A patent/JP2009513504A/ja active Pending
- 2004-06-29 DE DE602004007387T patent/DE602004007387T2/de not_active Expired - Fee Related
- 2004-06-29 BR BRPI0412163-5A patent/BRPI0412163A/pt not_active IP Right Cessation
- 2004-06-29 ES ES04740421T patent/ES2290726T3/es not_active Expired - Lifetime
- 2004-06-29 WO PCT/EP2004/007027 patent/WO2005005397A1/en not_active Ceased
- 2004-06-29 AT AT04740421T patent/ATE366242T1/de not_active IP Right Cessation
- 2004-06-29 AU AU2004255585A patent/AU2004255585A1/en not_active Abandoned
- 2004-06-29 CA CA002530450A patent/CA2530450A1/en not_active Abandoned
- 2004-06-29 KR KR1020057025234A patent/KR100737036B1/ko not_active Expired - Fee Related
- 2004-06-29 RU RU2006102867/04A patent/RU2006102867A/ru not_active Application Discontinuation
- 2004-06-29 PL PL04740421T patent/PL1644343T3/pl unknown
- 2004-06-29 EP EP04740421A patent/EP1644343B1/en not_active Expired - Lifetime
- 2004-06-29 MX MXPA06000185A patent/MXPA06000185A/es active IP Right Grant
- 2004-06-29 CN CNA2004800250463A patent/CN1845908A/zh active Pending
- 2004-07-01 TW TW093119907A patent/TW200514782A/zh unknown
- 2004-07-02 AR ARP040102347A patent/AR045006A1/es unknown
- 2004-07-02 US US10/884,595 patent/US20050124607A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004007387D1 (de) | 2007-08-16 |
| EP1644343A1 (en) | 2006-04-12 |
| JP2009513504A (ja) | 2009-04-02 |
| US20050124607A1 (en) | 2005-06-09 |
| CN1845908A (zh) | 2006-10-11 |
| DE602004007387T2 (de) | 2008-03-06 |
| BRPI0412163A (pt) | 2006-08-22 |
| CA2530450A1 (en) | 2005-01-20 |
| KR100737036B1 (ko) | 2007-07-09 |
| PL1644343T3 (pl) | 2007-12-31 |
| TW200514782A (en) | 2005-05-01 |
| KR20060027824A (ko) | 2006-03-28 |
| ATE366242T1 (de) | 2007-07-15 |
| AU2004255585A1 (en) | 2005-01-20 |
| ES2290726T3 (es) | 2008-02-16 |
| MXPA06000185A (es) | 2006-04-11 |
| EP1644343B1 (en) | 2007-07-04 |
| RU2006102867A (ru) | 2007-08-10 |
| WO2005005397A1 (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045006A1 (es) | Derivados de quinazolinona 5-sustituidos | |
| CO5580770A2 (es) | Compuestos de quinolina terapeuticos con propiedades antagonistas de 5-ht | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
| TW200738706A (en) | Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors | |
| KR960703852A (ko) | 이환상 테트라하이드로 피라졸로피리딘(bicyclic tetrahydro pyrazolopyridines) | |
| BG106594A (en) | Pteridinones as kinase inhibitors | |
| AR042586A1 (es) | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa | |
| AR001021A1 (es) | Derivados de pirazol-4-il-benzoilo, procedimiento para prepararlos, composiciones herbicidas formuladas con dichos derivados y procedimiento paracombatir el crecimiento de plantas indeseables con aplicacion de dichos derivados. | |
| AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
| CO5580826A2 (es) | Compuestos de quinolona terapeuticos con propiedades antagonistas de 5ht | |
| AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
| SE0104332D0 (sv) | Therapeutic agents | |
| AR035732A1 (es) | Derivados cromen-2-carboxilicos terapeuticos, uso de estos derivados para la preparacion de medicamentos, composicion farmaceutica, compuestos relacionados, y procesos para preparar estos compuestos relacionados | |
| AR036905A1 (es) | Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis | |
| CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| TN2011000380A1 (en) | Triazolopyridine derivatives as p38 map kinase inhibitors | |
| AR040048A1 (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 | |
| AR051638A1 (es) | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n | |
| AR111967A1 (es) | Amidas herbicidas | |
| AR035877A1 (es) | Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
| AR017189A1 (es) | Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento | |
| BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b | |
| AR043055A1 (es) | Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |